Online inquiry

IVTScrip™ mRNA-Anti-FGFR1, BMS-986036(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4643MR)

This product GTTS-WQ4643MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets FGFR1 gene. The antibody can be applied in Non-alcoholic steatohepatitis (NASH) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001174063.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2260
UniProt ID P11362
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FGFR1, BMS-986036(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ4643MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6946MR IVTScrip™ mRNA-Anti-TNF, ENIA11(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ENIA11
GTTS-WQ13849MR IVTScrip™ mRNA-Anti-GCGR, REGN-1193(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA REGN-1193
GTTS-WQ3955MR IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BFCR-4350-A
GTTS-WQ1265MR IVTScrip™ mRNA-Anti-EGFR, ABT-414(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABT-414
GTTS-WQ12908MR IVTScrip™ mRNA-Anti-FZD10, OTSA101-DTPA(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA OTSA101-DTPA
GTTS-WQ10630MR IVTScrip™ mRNA-Anti-MAPT, LY-3303560(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LY-3303560
GTTS-WQ4249MR IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BIIB031
GTTS-WQ10182MR IVTScrip™ mRNA-Anti-SELP, LC1004-002(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA LC1004-002
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW